CA3060410A1 - Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods - Google Patents
Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods Download PDFInfo
- Publication number
- CA3060410A1 CA3060410A1 CA3060410A CA3060410A CA3060410A1 CA 3060410 A1 CA3060410 A1 CA 3060410A1 CA 3060410 A CA3060410 A CA 3060410A CA 3060410 A CA3060410 A CA 3060410A CA 3060410 A1 CA3060410 A1 CA 3060410A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- acting
- cells
- long
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506494P | 2017-05-15 | 2017-05-15 | |
| US62/506,494 | 2017-05-15 | ||
| US201762536966P | 2017-07-25 | 2017-07-25 | |
| US62/536,966 | 2017-07-25 | ||
| US201762582186P | 2017-11-06 | 2017-11-06 | |
| US62/582,186 | 2017-11-06 | ||
| US201862648240P | 2018-03-26 | 2018-03-26 | |
| US62/648,240 | 2018-03-26 | ||
| PCT/US2018/032817 WO2018213341A1 (en) | 2017-05-15 | 2018-05-15 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3060410A1 true CA3060410A1 (en) | 2018-11-22 |
Family
ID=64274790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3060410A Pending CA3060410A1 (en) | 2017-05-15 | 2018-05-15 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12036283B2 (https=) |
| EP (1) | EP3624827A4 (https=) |
| JP (3) | JP7316222B2 (https=) |
| KR (2) | KR20250057110A (https=) |
| CN (2) | CN119700941A (https=) |
| AU (2) | AU2018270926C1 (https=) |
| CA (1) | CA3060410A1 (https=) |
| IL (2) | IL270634B2 (https=) |
| MX (2) | MX2019013621A (https=) |
| WO (1) | WO2018213341A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020097556A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| EP3946426A4 (en) * | 2019-04-05 | 2023-01-04 | Nektar Therapeutics | METHOD OF ENHANCING CELLULAR IMMUNOTHERAPY |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| IL288210B2 (en) | 2019-05-20 | 2026-03-01 | Cytune Pharma | Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| EP4232068A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| IL322075A (en) * | 2023-02-14 | 2025-09-01 | Akron Bioproducts Llc | Pharmaceutical compositions of interleukin for use in vivo |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| AU1096595A (en) | 1993-11-12 | 1995-05-29 | Gilead Sciences, Inc. | Thrombin mutants |
| WO1995027722A1 (en) | 1994-04-06 | 1995-10-19 | Immunex Corporation | Interleukin-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| GEP20084487B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| KR101207247B1 (ko) | 2003-01-06 | 2012-12-03 | 넥타르 테라퓨틱스 | 티올-선택성 수용성 중합체 유도체 |
| EP1670501A2 (en) | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| TW200613552A (en) | 2004-08-11 | 2006-05-01 | Hoffmann La Roche | Mutant interleukin-15 polypeptides |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| HUE025208T2 (en) | 2005-06-16 | 2016-03-29 | Nektar Therapeutics | Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates |
| EP2134181A4 (en) | 2007-02-28 | 2011-09-28 | Serina Therapeutics Inc | ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| PL2431741T3 (pl) | 2008-10-21 | 2014-01-31 | Baxalta Inc | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) |
| TR201908836T4 (tr) | 2010-07-30 | 2019-07-22 | Baxalta GmbH | Oksim bağına yönelik nükleofilik katalizörler. |
| WO2012065086A1 (en) * | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| WO2016060996A2 (en) * | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| WO2017062832A1 (en) | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
-
2018
- 2018-05-15 IL IL270634A patent/IL270634B2/en unknown
- 2018-05-15 CN CN202411943619.6A patent/CN119700941A/zh active Pending
- 2018-05-15 KR KR1020257012326A patent/KR20250057110A/ko active Pending
- 2018-05-15 CA CA3060410A patent/CA3060410A1/en active Pending
- 2018-05-15 IL IL318018A patent/IL318018A/en unknown
- 2018-05-15 US US16/613,757 patent/US12036283B2/en active Active
- 2018-05-15 AU AU2018270926A patent/AU2018270926C1/en active Active
- 2018-05-15 CN CN201880032373.3A patent/CN111093688B/zh active Active
- 2018-05-15 JP JP2019563255A patent/JP7316222B2/ja active Active
- 2018-05-15 EP EP18803095.1A patent/EP3624827A4/en active Pending
- 2018-05-15 WO PCT/US2018/032817 patent/WO2018213341A1/en not_active Ceased
- 2018-05-15 MX MX2019013621A patent/MX2019013621A/es unknown
- 2018-05-15 KR KR1020197036787A patent/KR102798243B1/ko active Active
-
2019
- 2019-11-14 MX MX2024009988A patent/MX2024009988A/es unknown
-
2022
- 2022-05-31 AU AU2022203691A patent/AU2022203691B2/en active Active
-
2023
- 2023-04-10 JP JP2023063333A patent/JP7772733B2/ja active Active
-
2024
- 2024-06-06 US US18/735,818 patent/US20240424115A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076268A patent/JP2025111770A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL270634B1 (en) | 2025-02-01 |
| JP7316222B2 (ja) | 2023-07-27 |
| KR20200003922A (ko) | 2020-01-10 |
| JP2020519676A (ja) | 2020-07-02 |
| US20200078467A1 (en) | 2020-03-12 |
| MX2019013621A (es) | 2020-01-13 |
| CN111093688B (zh) | 2025-09-16 |
| IL318018A (en) | 2025-02-01 |
| EP3624827A1 (en) | 2020-03-25 |
| IL270634A (en) | 2019-12-31 |
| AU2018270926B2 (en) | 2022-04-07 |
| AU2018270926A1 (en) | 2019-11-07 |
| IL270634B2 (en) | 2025-06-01 |
| KR102798243B1 (ko) | 2025-04-18 |
| US20240424115A1 (en) | 2024-12-26 |
| MX2024009988A (es) | 2024-08-27 |
| US12036283B2 (en) | 2024-07-16 |
| CN111093688A (zh) | 2020-05-01 |
| EP3624827A4 (en) | 2021-03-03 |
| AU2022203691A1 (en) | 2022-06-16 |
| JP7772733B2 (ja) | 2025-11-18 |
| JP2025111770A (ja) | 2025-07-30 |
| JP2023082218A (ja) | 2023-06-13 |
| AU2022203691B2 (en) | 2023-10-12 |
| CN119700941A (zh) | 2025-03-28 |
| AU2018270926C1 (en) | 2022-10-27 |
| KR20250057110A (ko) | 2025-04-28 |
| WO2018213341A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022203691B2 (en) | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods | |
| JP6728055B2 (ja) | Ｉｌ−１５部分とポリマーとのコンジュゲート | |
| JP2018154644A (ja) | Ｉｌ−２部分とポリマーとのコンジュゲート | |
| KR20170125839A (ko) | Ｉｌ-7 부분 및 중합체의 접합체 | |
| WO2022020637A1 (en) | Il-7 receptor agonist composition and related methods and uses | |
| EA043667B1 (ru) | Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения | |
| HK1235666A1 (en) | Conjugates of il-15 and branched polyethylene glycol | |
| HK1235666B (en) | Conjugates of il-15 and branched polyethylene glycol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220915 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250220 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250304 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250304 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250730 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |